According to a new report, published by KBV Research, The Global Automated And Closed Cell Therapy Processing Systems Market size is expected to reach USD 7.0 billion by 2033, rising at a market growth of 20.2% CAGR during the forecast period.
The Global Automated And Closed Cell Therapy Processing Systems Market is witnessing strong growth as healthcare organizations, biotechnology companies, pharmaceutical manufacturers, CDMOs, hospitals, and research institutes focus on improving efficiency, scalability, safety, and regulatory compliance in cell therapy manufacturing. Rising advancements in regenerative medicine, stem cell therapies, CAR-T cell therapies, personalized medicine, and advanced therapy medicinal products are increasing demand for automated, closed, contamination-free, and standardized processing systems.
The Non Stem Cell Therapy segment is leading the Global Automated And Closed Cell Therapy Processing Systems Market by Type in 2025; thereby, achieving a market value of USD 3.9 billion by 2033. Non stem cell therapy leads the market due to the increasing development and commercialization of immune cell therapies, particularly CAR-T, TCR-based therapies, NK cell therapies, and other engineered cell-based treatments. These therapies require complex processing steps such as cell collection, isolation, activation, expansion, genetic modification, washing, concentration, and final formulation, making automated and closed systems highly valuable.
The Pre-Commercial / R&D Scale segment is generating maximum revenue share in the Global Automated And Closed Cell Therapy Processing Systems Market by Scale in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 5.0 billion by 2033. Pre-commercial and R&D scale systems are widely adopted by academic institutions, biotechnology startups, research organizations, and early-stage cell therapy developers for process development, small-batch manufacturing, clinical trial material production, and protocol optimization. These systems support experimentation across diverse cell types and therapy formats while reducing contamination risk and improving process consistency.
The Separation segment is registering maximum revenue share in the Global Automated And Closed Cell Therapy Processing Systems Market by Workflow in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 2.0 billion by 2033. Separation leads the market due to its critical role in isolating target cells with high purity, viability, and consistency from complex biological samples such as peripheral blood or bone marrow. The segment is supported by the rising need for reliable, standardized, and closed cell isolation processes across autologous and allogeneic therapy manufacturing workflows.
Full Report: https://www.kbvresearch.com//
The North America region dominated the Global Automated And Closed Cell Therapy Processing Systems Market by Region in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 3.2 billion by 2033. The region’s dominance is supported by strong biopharmaceutical investments, advanced cell therapy manufacturing infrastructure, favorable regulatory support, high clinical trial activity, and increasing commercialization of CAR-T and other advanced therapies. Additionally, Europe is supported by expanding regenerative medicine research, strong ATMP regulatory frameworks, growing biomanufacturing capacity, and demand for GMP-compliant closed processing technologies, while Asia Pacific is witnessing strong growth due to rising biotechnology investments, increasing clinical research, expanding healthcare infrastructure, and growing cell therapy development.
By Type
By Scale
By Workflow
By Geography
Unique Offerings
